Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414348 | 0.86 | DGAT1 (0.40) | DGAT1CTSK | |
| SCHEMBL16885807 | 0.81 | DGAT1 (0.37) | DGAT1CTSK | |
| SCHEMBL10968666 | 0.81 | — | — | |
| SCHEMBL3489322 | 0.79 | DGAT1 (0.36) | DGAT1CTSK | |
| SCHEMBL1088416 | 0.79 | CTSK (0.38) | DGAT1CTSK | |
| SCHEMBL3955007 | 0.78 | — | — | |
| SCHEMBL19912070 | 0.77 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL20657046 | 0.77 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL18186430 | 0.77 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL2946741 | 0.77 | DGAT1 (0.44) | DGAT1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428430-B2 | Oxabicyclo acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3853232-B1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2021-10-14 | — | — | US | disclosed |
| CN-113366000-A | Oxabicyclic acids as LPA antagonists | 百时美施贵宝公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3853232-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-106795146-B | Isoxazole derivatives as inhibitors of mutant isocitrate dehydrogenase 1 | 第一三共株式会社 | 2020-06-26 | — | — | CN | disclosed |
| WO-2020060914-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3202766-A1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | IDH1, IDH3A, IDH3B | DGAT1 2881/4885CTSK 4469/4885 |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | IDH1, IDH3A, IDH3B | DGAT1 2881/4885CTSK 4469/4885 |
| US-12428430-B2 | Oxabicyclo acids as LPA antagonists | LPAR1, LPAR2, LPAR3 | DGAT1 214/4885CTSK 3493/4885 |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | DGAT1 214/4885CTSK 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.